Annual Meeting Proceedings, Part 2American Society of Clinical Oncology, 2007 |
From inside the book
6 pages matching statistically significant in this book
Where's the rest of this book?
Results 1-3 of 6
Other editions - View all
Common terms and phrases
analysis ASCO AstraZeneca Background BEACOPP breast cancer Bristol-Myers Squibb CALGB Cancer Center Hospital Cancer Oral Presentation Canfosfamide carboplatin chemotherapy cisplatin Clinical Oncology compared Conclusions cycles disclosure disease docetaxel dose doxorubicin ECOG efficacy EGFR eligible EORTC gefitinib gemcitabine Germany grade hazard ratio hazard ratio HR HBV reactivation Hoffman-La Roche immediate family member-defined involving the sharing Italy Japan Journal of Clinical larynx lenalidomide lung cancer Lung Cancer Oral matter under consideration median age median follow-up Median PFS median survival median TTP member-defined as someone metastatic Methods mg/m² months neutropenia non-inferiority NSCLC Oncology overall survival paclitaxel patients pts phase III study phase III trial primary endpoint pts received R+HighD R+LowD randomized phase rash regimen Research resistant OC respectively response rate Results sanofi-aventis Secondary endpoints sharing of income Sorafenib ST-A ST-B tetracycline therapy toxicity trastuzumab treatment United Kingdom University Hospital versus vinorelbine weeks